Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell...

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Diffuse large B cell lymphoma (DLBCL) requires improved therapies.
• Cancer testis antigens (CTAs) are promising immunotherapeutic targets due to their tumor-specific expression.
• Sperm protein 17 (Sp17), a CTA, is expressed in DLBCL and has shown immunogenicity in other cancers.

Purpose of the Study:

• To investigate the presentation of Sp17 epitopes in DLBCL patients.
• To assess cytotoxic T cell (CTL) and CD4 T-helper (Th) responses to Sp17 in DLBCL.

Main Methods:

• Stimulation of peripheral blood mononuclear cells (PBMCs) from DLBCL patients with Sp17 peptides.
• Detection of gamma-interferon (γ-IFN) release as a marker of CTL response.
• Identification of CD4 Th responses using novel Sp17 peptides.

Main Results:

• A significant CTL response to Sp17 peptides was observed in 13/31 DLBCL patients.
• No significant CTL responses were detected in HLA-A*0201-negative DLBCL patients or healthy controls.
• A novel immunogenic CD4 Th response to an Sp17 peptide was detected in 8/17 DLBCL patients.

Conclusions:

• This study provides the first evidence of both CTL and CD4 Th responses to Sp17 in DLBCL patients.
• Sp17 is a potential immunotherapeutic target for DLBCL.
• Further research into Sp17-based immunotherapies for DLBCL is warranted.